Meridian Bioscience (VIVO) Tops Q4 EPS by 4c, Revenue Beat; Offers FY19 EPS Guidance Below Consensus

Meridian Bioscience (NASDAQ: VIVO) reported Q4 EPS of $0.20, $0.04 better than the analyst estimate of $0.16. Revenue for the quarter came in at $53.1 million versus the consensus estimate of $51.11 million.

Jack Kenny, Chief Executive Officer, commented, “We are pleased to report these very positive fourth quarter and full-year results, and believe that they are starting to demonstrate the effectiveness of the realignment and streamlining activities we initiated earlier this year. In addition to very solid finishes to the year in both of our segments, the fourth quarter also included a number of noteworthy corporate governance events including the addition of a new Board member, the appointment of a new Chairman of the Board and the retirement of long time Meridian CEO and Chairman, Jack Kraeutler. On the operational front, the fourth quarter also saw us negotiate a strategic collaboration agreement with DiaSorin to sell Helicobacter Pylori tests, resulting in a signed agreement in early October – an agreement we are confident will be mutually beneficial for both our organizations for years to come. We are eager and excited to build upon these successes and continue the momentum as we progress through fiscal 2019.”

GUIDANCE:

Meridian Bioscience sees FY2019 EPS of $0.74-$0.76, versus the consensus of $0.77.

For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.

You May Also Be Interested In

• BayCom Corp (BCML) Misses Q1 EPS by 4c
• Glacier Bancorp (GBCI) Misses Q1 EPS by 3c
• Marten Transport (MRTN) Misses Q1 EPS by 2c